List of Figures:
Figure 1. Research Method Flow Chart 12
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 17
Figure 4. Europe Pharmacovigilance and Drug Safety Software Market, 2021-2031, $ mn 20
Figure 5. Impact of COVID-19 on Business 25
Figure 6. Primary Drivers and Impact Factors of Europe Pharmacovigilance and Drug Safety Software Market 27
Figure 7. Percentage of Trial Participants by Country, 2015-2019 30
Figure 8. World Drug Discovery Market, 2019-2030, $ mn 31
Figure 9. Primary Restraints and Impact Factors of Europe Pharmacovigilance and Drug Safety Software Market 32
Figure 10. Investment Opportunity Analysis 36
Figure 11. Porter’s Fiver Forces Analysis of Europe Pharmacovigilance and Drug Safety Software Market 39
Figure 12. Breakdown of Europe Pharmacovigilance and Drug Safety Software Market by Functionality, 2021-2031, % of Revenue 44
Figure 13. Europe Addressable Market Cap in 2022-2031 by Functionality, Value ($ mn) and Share (%) 44
Figure 14. Europe Pharmacovigilance and Drug Safety Software Market by Functionality: Adverse Event Reporting Software, 2021-2031, $ mn 45
Figure 15. Europe Pharmacovigilance and Drug Safety Software Market by Functionality: Drug Safety Audits Software, 2021-2031, $ mn 46
Figure 16. Europe Pharmacovigilance and Drug Safety Software Market by Functionality: Issue Tracking Software, 2021-2031, $ mn 47
Figure 17. Europe Pharmacovigilance and Drug Safety Software Market by Functionality: Fully Integrated Software, 2021-2031, $ mn 48
Figure 18. Breakdown of Europe Pharmacovigilance and Drug Safety Software Market by Clinical Phase, 2021-2031, % of Sales Revenue 50
Figure 19. Europe Addressable Market Cap in 2022-2031 by Clinical Phase, Value ($ mn) and Share (%) 50
Figure 20. Europe Pharmacovigilance and Drug Safety Software Market by Clinical Phase: Pre-clinical, 2021-2031, $ mn 51
Figure 21. Europe Pharmacovigilance and Drug Safety Software Market by Clinical Phase: Phase I, 2021-2031, $ mn 52
Figure 22. Europe Pharmacovigilance and Drug Safety Software Market by Clinical Phase: Phase II, 2021-2031, $ mn 53
Figure 23. Europe Pharmacovigilance and Drug Safety Software Market by Clinical Phase: Phase III, 2021-2031, $ mn 54
Figure 24. Europe Pharmacovigilance and Drug Safety Software Market by Clinical Phase: Phase IV, 2021-2031, $ mn 55
Figure 25. Breakdown of Europe Pharmacovigilance and Drug Safety Software Market by Method, 2021-2031, % of Sales Revenue 57
Figure 26. Europe Addressable Market Cap in 2022-2031 by Method, Value ($ mn) and Share (%) 57
Figure 27. Europe Pharmacovigilance and Drug Safety Software Market by Method: Spontaneous Reporting, 2021-2031, $ mn 58
Figure 28. Europe Pharmacovigilance and Drug Safety Software Market by Method: Intensified ADR Reporting, 2021-2031, $ mn 59
Figure 29. Europe Pharmacovigilance and Drug Safety Software Market by Method: Targeted Spontaneous Reporting, 2021-2031, $ mn 60
Figure 30. Europe Pharmacovigilance and Drug Safety Software Market by Method: Cohort Event Monitoring, 2021-2031, $ mn 61
Figure 31. Europe Pharmacovigilance and Drug Safety Software Market by Method: EHR Mining, 2021-2031, $ mn 62
Figure 32. Breakdown of Europe Pharmacovigilance and Drug Safety Software Market by Delivery Mode, 2021-2031, % of Revenue 64
Figure 33. Europe Addressable Market Cap in 2022-2031 by Delivery Mode, Value ($ mn) and Share (%) 64
Figure 34. Europe Pharmacovigilance and Drug Safety Software Market by Delivery Mode: On-premise Delivery, 2021-2031, $ mn 65
Figure 35. Europe Pharmacovigilance and Drug Safety Software Market by Delivery Mode: On-demand Delivery, 2021-2031, $ mn 66
Figure 36. Breakdown of Europe Pharmacovigilance and Drug Safety Software Market by Indication, 2021-2031, % of Revenue 68
Figure 37. Europe Addressable Market Cap in 2022-2031 by Indication, Value ($ mn) and Share (%) 68
Figure 38. Europe Pharmacovigilance and Drug Safety Software Market by Indication: Oncology, 2021-2031, $ mn 69
Figure 39. Europe Pharmacovigilance and Drug Safety Software Market by Indication: Respiratory Disorders, 2021-2031, $ mn 70
Figure 40. Europe Pharmacovigilance and Drug Safety Software Market by Indication: Cardiology, 2021-2031, $ mn 71
Figure 41. Europe Pharmacovigilance and Drug Safety Software Market by Indication: Neurology, 2021-2031, $ mn 72
Figure 42. Europe Pharmacovigilance and Drug Safety Software Market by Indication: Immunology, 2021-2031, $ mn 73
Figure 43. Europe Pharmacovigilance and Drug Safety Software Market by Indication: Pain Management, 2021-2031, $ mn 74
Figure 44. Europe Pharmacovigilance and Drug Safety Software Market by Indication: Other Indications, 2021-2031, $ mn 75
Figure 45. Breakdown of Europe Pharmacovigilance and Drug Safety Software Market by End User, 2021-2031, % of Revenue 76
Figure 46. Europe Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%) 77
Figure 47. Europe Pharmacovigilance and Drug Safety Software Market by End User: Pharmaceutical and Biotechnology Companies, 2021-2031, $ mn 78
Figure 48. Europe Pharmacovigilance and Drug Safety Software Market by End User: Contract Research Organizations (CROs), 2021-2031, $ mn 79
Figure 49. Europe Pharmacovigilance and Drug Safety Software Market by End User: Business Process Outsourcing Firms (BPOs), 2021-2031, $ mn 80
Figure 50. Europe Pharmacovigilance and Drug Safety Software Market by End User: Other End Users, 2021-2031, $ mn 81
Figure 51. Breakdown of European Pharmacovigilance and Drug Safety Software Market by Country, 2021 and 2031, % of Revenue 83
Figure 52. Contribution to Europe 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 84
Figure 53. Pharmacovigilance and Drug Safety Software Market in Germany, 2021-2031, $ mn 85
Figure 54. Pharmacovigilance and Drug Safety Software Market in U.K., 2021-2031, $ mn 88
Figure 55. Pharmacovigilance and Drug Safety Software Market in France, 2021-2031, $ mn 90
Figure 56. Pharmacovigilance and Drug Safety Software Market in Spain, 2021-2031, $ mn 92
Figure 57. Pharmacovigilance and Drug Safety Software Market in Italy, 2021-2031, $ mn 94
Figure 58. Pharmacovigilance and Drug Safety Software Market in Netherlands, 2021-2031, $ mn 96
Figure 59. Pharmacovigilance and Drug Safety Software Market in Rest of Europe, 2021-2031, $ mn 98
Figure 60. Growth Stage of Europe Pharmacovigilance and Drug Safety Software Industry over the Forecast Period 100
Europe pharmacovigilance and drug safety software market was valued at $61.1 million in 2021 and will grow by 7.4% annually over 2021-2031, driven by the increasing prevalence of chronic diseases due to the aging population, the growing drug discovery pipelines, increase in incidence of adverse drug reactions (ADR), more stringent regulatory guidelines for drug safety, and the increasing adoption of AI and cloud technologies in PV software and solutions. Highlighted with 33 tables and 60 figures, this 119-page report “Europe Pharmacovigilance and Drug Safety Software Market 2021-2031 by Functionality (Adverse Event Reporting, Drug Safety Audits, Issue Tracking, Fully Integrated), Clinical Phase (Pre-clinical, Phase I-IV), Method, Delivery Mode (On-premise, On-demand), Indication, End User (Pharma and Biotech Companies, CROs, BPOs, Others), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe pharmacovigilance and drug safety software market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Europe pharmacovigilance and drug safety software market in every aspect of the classification from perspectives of Functionality, Clinical Phase, Method, Delivery Mode, Indication, End User, and Country. Based on Functionality, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Adverse Event Reporting Software • Drug Safety Audits Software • Issue Tracking Software • Fully Integrated Software Based on Clinical Phase, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Pre-clinical • Phase I • Phase II • Phase III • Phase IV By Method, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Spontaneous Reporting • Intensified ADR Reporting • Targeted Spontaneous Reporting • Cohort Event Monitoring • EHR Mining By Delivery Mode, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • On-premise Delivery • On-demand Delivery By Indication, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Oncology • Respiratory Disorders • Cardiology • Neurology • Immunology • Pain Management • Other Indications By End Users, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Pharmaceutical and Biotechnology Companies • Contract Research Organizations (CROs) • Business Process Outsourcing Firms (BPOs) • Other End Users Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Netherlands • Rest of Europe (further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Functionality, Delivery Mode and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Ab Cube Accenture PLC ArisEurope LLC Cognizant Technology Solutions Corporation Ennov Solutions Inc. Extedo GmbH Honeywell International Inc. (Sparta Systems Inc.) IQVIA Inc. Max Application Oracle Corporation Sarjen Systems Pvt. Ltd. United BioSource LLC Veeva Systems Inc. Wipro Limited (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More